$OPRX
OptimizeRx Corp Stock $oprx

$oprx Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000121390024033000 Filed on April 15, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue	$18.81M	$28.37M	$71.52M
YoY Change	36.14%	44.34%	14.53%
Cost Of Revenue	$7.108M	$10.53M	$28.62M
YoY Change	18.6%	46.22%	21.88%
Gross Profit	$11.70M	$17.84M	$42.90M
YoY Change	49.57%	43.25%	10.09%
Gross Profit Margin	62.22%	62.89%	59.98%
Selling, General & Admin	$14.38M	$18.86M	$58.02M
YoY Change	17.46%	-29.3%	73.25%
% of Gross Profit	122.86%	105.7%	135.25%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$1.073M	$1.002M	$2.402M
YoY Change	130.87%	119.39%	18.77%
% of Gross Profit	9.17%	5.61%	5.6%
Operating Expenses	$15.45M	$19.86M	$60.42M
YoY Change	21.61%	49.15%	17.88%
Operating Profit	-$3.749M	-$2.023M	-$17.52M
YoY Change	-23.21%	134.08%	42.56%
Interest Expense	-$1.422M	-$1.336M	$737.9K
YoY Change	-297.38%	-348.12%	-13.42%
% of Operating Profit
Other Income/Expense, Net	-$1.347M	$500.0K	$500.0K
YoY Change	-286.97%		-41.34%
Pretax Income	-$5.096M	-$11.74M	-$25.16M
YoY Change	22.46%	3502.79%	119.99%
Income Tax	-$1.088M	-$7.598M	-$7.598M
% Of Pretax Income
Net Earnings	-$4.008M	-$4.141M	-$17.57M
YoY Change	-3.69%	1170.99%	53.57%
Net Earnings / Revenue	-21.31%	-14.6%	-24.56%
Basic Earnings Per Share	-$0.22		-$1.03
Diluted Earnings Per Share	-$0.22	-$0.23	-$1.03
COMMON SHARES
Basic Shares Outstanding	18.18M shares	18.15M shares	17.12M shares
Diluted Shares Outstanding	18.26M shares		17.12M shares

Balance Sheet

Concept	2024 Q2	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$14.96M	$13.85M	$13.85M
YoY Change	-76.16%	-81.32%	-81.32%
Cash & Equivalents	$14.96M	$13.85M	$13.85M
Short-Term Investments		$0.00	$0.00
Other Short-Term Assets	$4.647M	$3.189M	$3.189M
YoY Change	14.66%	39.84%	39.84%
Inventory
Prepaid Expenses
Receivables	$24.52M	$36.25M	$36.25M
Other Receivables	$1.842M	$1.036M	$1.036M
Total Short-Term Assets	$45.97M	$54.33M	$54.33M
YoY Change	-45.97%	-44.88%	-44.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$171.0K	$722.3K	$722.3K
YoY Change	21.3%	425.51%	93.77%
Goodwill	$78.36M	$78.36M
YoY Change	245.58%	245.58%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$434.0K	$568.1K	$568.1K
YoY Change		11148.51%	11148.51%
Total Long-Term Assets	$126.9M	$129.0M	$129.0M
YoY Change	250.08%	257.71%	257.71%
TOTAL ASSETS
Total Short-Term Assets	$45.97M	$54.33M	$54.33M
Total Long-Term Assets	$126.9M	$129.0M	$129.0M
Total Assets	$172.9M	$183.4M	$183.4M
YoY Change	42.49%	36.18%	36.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.980M	$2.227M	$2.227M
YoY Change	264.4%	43.69%	43.69%
Accrued Expenses	$5.310M	$7.976M	$7.976M
YoY Change	253.18%	206.64%	196.39%
Deferred Revenue	$1.054M	$172.0K
YoY Change	133.7%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.300M	$2.000M	$2.000M
YoY Change
Total Short-Term Liabilities	$14.96M	$17.88M	$17.88M
YoY Change	171.45%	112.98%	112.98%
LONG-TERM LIABILITIES
Long-Term Debt	$32.30M	$34.23M	$34.23M
YoY Change
Other Long-Term Liabilities	$271.0K	$371.4K	$371.4K
YoY Change		157.0%	157.0%
Total Long-Term Liabilities	$32.30M	$34.60M	$34.60M
YoY Change			23841.17%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.96M	$17.88M	$17.88M
Total Long-Term Liabilities	$32.30M	$34.60M	$34.60M
Total Liabilities	$51.86M	$56.82M	$56.82M
YoY Change	841.25%	565.32%	565.32%
SHAREHOLDERS EQUITY
Retained Earnings	-$75.17M	-$64.26M
YoY Change	31.29%	37.62%
Common Stock	$20.00K	$19.90K
YoY Change	8.83%	8.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.000K	$1.741K
YoY Change	14.88%	43.41%
Treasury Stock Shares
Shareholders Equity	$121.0M	$126.6M	$126.6M
YoY Change
Total Liabilities & Shareholders Equity	$172.9M	$183.4M	$183.4M
YoY Change	42.49%	36.18%	36.18%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$4.008M	-$4.141M	-$17.57M
YoY Change	-3.69%	1170.99%	53.57%
Depreciation, Depletion And Amortization	$1.073M	$1.002M	$2.402M
YoY Change	130.87%	119.39%	18.77%
Cash From Operating Activities	$782.0K	-$6.259M	-$7.239M
YoY Change	-133.02%	-323.26%	-167.95%
INVESTING ACTIVITIES
Capital Expenditures	$85.00K	-$778.6K	$871.4K
YoY Change	-92.3%	-537.23%	975.76%
Acquisitions			$82.95M
YoY Change			4047.36%
Other Investing Activities		-$26.78M	-$24.47M
YoY Change		46.26%	-57.77%
Cash From Investing Activities	-$85.00K	-$26.00M	-$25.34M
YoY Change	-102.64%	40.64%	-56.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			-$7.800M
YoY Change			-138.95%
Debt Paid & Issued, Net			$1.710M
YoY Change
Cash From Financing Activities	-915.0K	36.19M	28.22M
YoY Change	-87.78%	-586.47%	-248.91%
NET CHANGE
Cash From Operating Activities	782.0K	-6.259M	-7.239M
Cash From Investing Activities	-85.00K	-26.00M	-25.34M
Cash From Financing Activities	-915.0K	36.19M	28.22M
Net Change In Cash	-218.0K	3.934M	-4.356M
YoY Change	-96.71%	-117.01%	-93.45%
FREE CASH FLOW
Cash From Operating Activities	$782.0K	-$6.259M	-$7.239M
Capital Expenditures	$85.00K	-$778.6K	$871.4K
Free Cash Flow	$697.0K	-$5.481M	-$8.111M
YoY Change	-120.08%	-308.75%	-176.71%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	75784	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38543
CY2023	dei	Entity Registrant Name EntityRegistrantName	OptimizeRx Corporation
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	260 Charles Street
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 302
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Waltham
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02453
CY2023	dei	City Area Code CityAreaCode	248
CY2023	dei	Local Phone Number LocalPhoneNumber	651-6568
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001
CY2023	dei	Trading Symbol TradingSymbol	OPRX
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	235326034	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	18183914	shares
CY2023	dei	Auditor Firm AuditorFirmId	1195
CY2023	dei	Auditor Name AuditorName	UHY LLP
CY2023	dei	Auditor Location AuditorLocation	Sterling Heights, Michigan
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13852456	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18208685	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	55931821	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	239172	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	352043	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	36253214	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	22155301	usd
CY2023Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	1035754	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3189468	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2280828	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	54330892	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	98576635	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	149407	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	137448	usd
CY2023Q4	us-gaap	Goodwill Goodwill	78357074	usd
CY2022Q4	us-gaap	Goodwill Goodwill	22673820	usd
CY2023Q4	oprx	Patent Rights Net Non Current PatentRightsNetNonCurrent	6184742	usd
CY2022Q4	oprx	Patent Rights Net Non Current PatentRightsNetNonCurrent	1940178	usd
CY2023Q4	oprx	Technology Assets Net TechnologyAssetsNet	9012756	usd
CY2022Q4	oprx	Technology Assets Net TechnologyAssetsNet	7702895	usd
CY2023Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	34198084	usd
CY2022Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	3379838	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	572895	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	235320	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	568048	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	5051	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	128893599	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	35937102	usd
CY2023Q4	us-gaap	Assets Assets	183373898	usd
CY2022Q4	us-gaap	Assets Assets	134651185	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2000000	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2227177	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1549979	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7754781	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2601246	usd
CY2023Q4	oprx	Revenue Share Payable Current RevenueSharePayableCurrent	5505701	usd
CY2022Q4	oprx	Revenue Share Payable Current RevenueSharePayableCurrent	3990440	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	221625	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	89902	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	171841	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	164309	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17881125	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8395876	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	34230737	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	371438	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	144532	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4337424	usd
CY2023Q4	us-gaap	Liabilities Liabilities	56820724	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8540408	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	166666667	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	166666667	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19899679	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18288571	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	19899	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	18289	usd
CY2023Q4	oprx	Treasury Stock Par Value TreasuryStockParValue	0.001
CY2022Q4	oprx	Treasury Stock Par Value TreasuryStockParValue	0.001
CY2023Q4	oprx	Treasury Stock Shares Purchased TreasuryStockSharesPurchased	1741397	shares
CY2022Q4	oprx	Treasury Stock Shares Purchased TreasuryStockSharesPurchased	1214398	shares
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1741	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1214	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	190792980	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	172785800	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-64257964	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-46692098	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	126553174	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	126110777	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	183373898	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	134651185	usd
CY2023	us-gaap	Revenues Revenues	71521506	usd
CY2022	us-gaap	Revenues Revenues	62450156	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	28621589	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	23483336	usd
CY2023	us-gaap	Gross Profit GrossProfit	42899917	usd
CY2022	us-gaap	Gross Profit GrossProfit	38966820	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	13717333	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	15745822	usd
CY2023	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-2142319	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	6737580	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2401628	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2022029	usd
CY2023	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	44302771	usd
CY2022	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	33489707	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	69301631	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	51257558	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-26401714	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-12290738	usd
CY2023	us-gaap	Interest Expense InterestExpense	1453764	usd
CY2023	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	500001	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	2191689	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	852298	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1237926	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	852298	usd
CY2023	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-25163788	usd
CY2022	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-11438440	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7597922	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-17565866	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-11438440	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17124801	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17783992	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17124801	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17783992	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.03
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.64
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.03
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.64
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	126110777	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	5925416	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	7791917	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	181106	usd
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	12091142	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-458892	usd
CY2023	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	7522426	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-17565866	usd
CY2022	oprx	Proceeds From Exercise Of Stock Options Net Of Cash Paid For Withholding Taxes ProceedsFromExerciseOfStockOptionsNetOfCashPaidForWithholdingTaxes	1073481	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28219789	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	126553174	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	131379717	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	4956619	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	10789203	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1205881	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	9374455	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-132400	usd
CY2022	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	20024258	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-11438440	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	126110777	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-17565866	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-11438440	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2401628	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2022029	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	6737580	usd
CY2023	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	-2142319	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	665973	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	363512	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	13717333	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	15745822	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	210737	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8712954	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2281773	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	573333	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2650951	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1320150	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	943171	usd
CY2023	oprx	Increase Decrease In Revenue Share Payable IncreaseDecreaseInRevenueSharePayable	1515262	usd
CY2022	oprx	Increase Decrease In Revenue Share Payable IncreaseDecreaseInRevenueSharePayable	-387776	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	1305164	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-301366	usd
CY2023	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	7695374	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-67472	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1225598	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7239153	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	10654078	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	87073	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	81005	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	10000	usd
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	82947264	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	2000000	usd
CY2023	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	2540000	usd
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	162777510	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	55931821	usd
CY2023	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	218709331	usd
CY2023	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	784349	usd
CY2022	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	163560	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-25336865	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-58176386	usd
CY2023	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet	37730000	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1710000	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	7522426	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	20024258	usd
CY2023	oprx	Proceeds From Exercise Of Stock Options Net Of Cash Paid For Withholding Taxes ProceedsFromExerciseOfStockOptionsNetOfCashPaidForWithholdingTaxes	-277785	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Reclassifications</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Certain items in the previous year financial statements have been reclassified to match the current year presentation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-18950777	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4356229	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-66473085	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18208685	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84681770	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13852456	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18208685	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	1212619	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	459580	usd
CY2022	oprx	Reduction Of Evince Med Purchase Price For Amounts Previously Paid ReductionOfEvinceMedPurchasePriceForAmountsPreviouslyPaid	708334	usd
CY2023	oprx	Shares Issued In Connection With Acquisitions SharesIssuedInConnectionWithAcquisitions	12091142	usd
CY2022	oprx	Shares Issued In Connection With Acquisitions SharesIssuedInConnectionWithAcquisitions	9374455	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	48222	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">OptimizeRx is a digital health technology company enabling care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. Connecting over two million U.S. healthcare providers and millions of their patients through an intelligent technology platform embedded within a proprietary point-of-care network, as well as mass digital communications channels, OptimizeRx helps life sciences organizations engage and support their customers.</span></p>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Use of Estimates</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates and assumptions have been made in determining the allowance for credit losses, carrying value of assets, fair values assigned to acquired long-lived assets, depreciable and amortizable lives of tangible and intangible assets, the carrying value of liabilities, the valuation allowance for deferred tax assets, the timing of revenue recognition and related revenue-share expenses, and inputs used in the calculation of stock based compensation. Actual results could differ from these estimates.</span></p>
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	665973	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	363512	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	239172	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	352043	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	352043	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	241219	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	665973	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	363512	usd
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	778844	usd
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	252688	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	239172	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	352043	usd
CY2023Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	4198312	usd
CY2022Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	3582735	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	6700000	usd
CY2023Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	2000000	usd
CY2022Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	5400000	usd
CY2023	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	63527477	usd
CY2022	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	55437418	usd
CY2023	oprx	Revenue Recognized Time RevenueRecognizedTime	7994029	usd
CY2022	oprx	Revenue Recognized Time RevenueRecognizedTime	7012738	usd
CY2023	us-gaap	Revenues Revenues	71521506	usd
CY2022	us-gaap	Revenues Revenues	62450156	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements EffectiveIncomeTaxRateReconciliationTaxSettlements	0.50	pure
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Concentration of Credit Risks</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company maintains its cash and cash equivalents in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts; however, amounts in excess of the federally insured limit may be at risk if the bank experiences financial difficulties. As of December 31, 2023 and 2022 the Company had $13,260,816 and $15,669,837, respectively, in cash balances in excess of federally insured limits, primarily at Bank of America.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	13260816	usd
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	15669837	usd
CY2023	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	775548	usd
CY2022	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	743975	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y6M
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y6M
CY2023	oprx	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Turnoverforfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsTurnoverforfeitureRate	0	pure
CY2022	oprx	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Turnoverforfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsTurnoverforfeitureRate	0	pure
CY2023	oprx	Weighted Average Grant Date Fair Valuein Dollars Per Share WeightedAverageGrantDateFairValueinDollarsPerShare	6.58
CY2022	oprx	Weighted Average Grant Date Fair Valuein Dollars Per Share WeightedAverageGrantDateFairValueinDollarsPerShare	12.82
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	31727	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	93626	shares
CY2023	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	52607	shares
CY2022	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	170859	shares
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17565866	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17124801	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.03
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-17565866	usd
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17124801	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.03
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11438440	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17783992	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.64
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-11438440	usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17783992	shares
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.64
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	1	pure
CY2023	us-gaap	Asset Acquisition Consideration Transferred Contingent Consideration AssetAcquisitionConsiderationTransferredContingentConsideration	83888239	usd
CY2023	us-gaap	Asset Acquisition Consideration Transferred Equity Interest Issued And Issuable AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable	12091142	usd
CY2023	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	95979381	usd
CY2023	us-gaap	Federal State And Local Income Tax Expense Benefit Continuing Operations FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations	1000000	usd
CY2023Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	1000000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	1000000	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	940974	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables	6028048	usd
CY2023Q4	oprx	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Taxes Receivable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentTaxesReceivable	1035754	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets	912719	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	33476	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Indefinite Lived Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets	34000000	usd
CY2023Q4	oprx	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Trademark And Patent Intangible BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademarkAndPatentIntangible	5700000	usd
CY2023Q4	oprx	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Technology Intangibles BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTechnologyIntangibles	8300000	usd
CY2023Q4	oprx	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Rightofuse Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightofuseAssets	145075	usd
CY2023Q4	oprx	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deposits BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeposits	9727	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	57105773	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	1997348	usd
CY2023Q4	oprx	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Expenses BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses	3848403	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Capital Lease Obligation BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation	166098	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Deferred Revenue BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue	75003	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities	12032798	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities	18119650	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	38986123	usd
CY2023Q4	us-gaap	Goodwill Gross GoodwillGross	56993258	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	95979381	usd
CY2023	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	97066241	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	90521236	usd
CY2023	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-18616303	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-16157521	usd
CY2022Q2	oprx	Issuance Of Shares Of Common Stock IssuanceOfSharesOfCommonStock	240741	shares
CY2022Q2	oprx	Business Acquisition Common Stock Value BusinessAcquisitionCommonStockValue	9374455	usd
CY2022Q2	oprx	Purchase Price PurchasePrice	12082789	usd
CY2022Q2	us-gaap	Shares Issued SharesIssued	185185	shares
CY2022Q2	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P8Y
CY2022Q2	us-gaap	Goodwill Gross GoodwillGross	7933789	usd
CY2022Q2	oprx	Goodwill Deductible Tax Life GoodwillDeductibleTaxLife	P15Y
CY2022Q2	us-gaap	Acquisition Costs AcquisitionCosts	19739	usd
CY2022Q4	us-gaap	Assets Held In Trust AssetsHeldInTrust	55900000	usd
CY2023Q4	oprx	Revenue Share And Exclusivity Payments RevenueShareAndExclusivityPayments	1495127	usd
CY2022Q4	oprx	Revenue Share And Exclusivity Payments RevenueShareAndExclusivityPayments	1025000	usd
CY2023Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	407480	usd
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	408063	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	369504	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	221580	usd
CY2023Q4	oprx	Property Plantand Equipment Data PropertyPlantandEquipmentData	513244	usd
CY2022Q4	oprx	Property Plantand Equipment Data PropertyPlantandEquipmentData	152533	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	404113	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	473652	usd
CY2023Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	3189468	usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	2280828	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	300269	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	268967	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	150862	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	131519	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	149407	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	137448	usd
CY2023	us-gaap	Depreciation Depreciation	99849	usd
CY2022	us-gaap	Depreciation Depreciation	85725	usd
CY2021Q4	us-gaap	Goodwill Goodwill	14740031	usd
CY2022	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	7933789	usd
CY2022Q4	us-gaap	Goodwill Goodwill	22673820	usd
CY2023	oprx	Acquisitions On Goodwill AcquisitionsOnGoodwill	56993258	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1310004	usd
CY2023Q4	us-gaap	Goodwill Goodwill	78357074	usd
CY2023	oprx	Transaction Due TransactionDue	3740000	usd
CY2023	oprx	Access Products AccessProducts	2540000	usd
CY2023	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	-2142319	usd
CY2023	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	1310004	usd
CY2023Q4	us-gaap	Sale Leaseback Transaction Net Book Value SaleLeasebackTransactionNetBookValue	3327844	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	55701351	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6305769	usd
CY2023Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	49395582	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	21826389	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8803478	usd
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	13022911	usd
CY2023	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	6737580	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Two FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo	2301779	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Two FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo	1936304	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	4202841	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	4128899	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	4079117	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3972613	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	3724330	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	29287782	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	49395582	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	171841	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	164309	usd
CY2022Q4	us-gaap	Common Stocks Including Additional Paid In Capital Net Of Discount CommonStocksIncludingAdditionalPaidInCapitalNetOfDiscount	20021830	usd
CY2022	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	1214398	shares
CY2022	us-gaap	Insurance Commissions InsuranceCommissions	20024258	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	164309	usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-12358640	usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	12291169	usd
CY2023	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	75003	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	171841	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1389907	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-13455253	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	12229655	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	164309	usd
CY2023	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	930000	usd
CY2023	oprx	Revenue From Contract RevenueFromContract	335897	usd
CY2022	oprx	Revenue From Contract RevenueFromContract	401972	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	166666667	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	24668	shares
CY2023	oprx	Gross Proceeds Of Common Stock Amount GrossProceedsOfCommonStockAmount	181106	usd
CY2022	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	156910	shares
CY2022	oprx	Gross Proceeds Of Common Stock Amount GrossProceedsOfCommonStockAmount	1205881	usd
CY2023	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	42489	shares
CY2022	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8416	shares
CY2023Q1	us-gaap	Common Stock Other Value Outstanding CommonStockOtherValueOutstanding	15000000	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	7522426	usd
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1214398	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	3000000	shares
CY2023	oprx	Shares Of Common Stock Options SharesOfCommonStockOptions	345435	shares
CY2023Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	1209626	shares
CY2023	oprx	Common Stock Restricted Stock Unit CommonStockRestrictedStockUnit	631581	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	276844	shares
CY2023	oprx	Fair Market Value Rate FairMarketValueRate	1	pure
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	783547	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	34.17
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	862938	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	25.43
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	156910	shares
CY2022	oprx	Weighted Average Exercise Price Exercised WeightedAverageExercisePriceExercised	7.69
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	182705	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	37.13
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1306870	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	31.14
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P2Y8M12D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1537752	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	426703	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	12.5
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	24668	shares
CY2023	oprx	Weighted Average Exercise Price Exercised WeightedAverageExercisePriceExercised	7.34
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	153844	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	30.7
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1555061	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	26.38
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P3Y4M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1046481	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	586274	shares
CY2023	oprx	Share Based Compensation Arrangements By Share Based Payment Award Options Exercisable In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice	33.1
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y7M6D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	239110	usd
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1056187	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	30.51
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	426703	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	12.5
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	381992	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	31.61
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	132111	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	52.07
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	968787	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	22.03
CY2023	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	8956198	usd
CY2023	oprx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2	P1Y9M7D
CY2021Q4	oprx	Sharebased Compensation Arrangement By Sharebased Payment Restricted Stock Awards Shares Outstanding Beginning SharebasedCompensationArrangementBySharebasedPaymentRestrictedStockAwardsSharesOutstandingBeginning	399738	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue	52.99
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	467043	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	25.69
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	39346	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	44.06
CY2022	oprx	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Shares Issued ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsSharesIssued	-29945	shares
CY2022	oprx	Weightedgrantdatefairvalue Sharesissued WeightedgrantdatefairvalueSharesissued	59.41
CY2022	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	8416	shares
CY2022	oprx	Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Grant Date Fair Value Withheld And Cancelled ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueWithheldAndCancelled	68.69
CY2022Q4	oprx	Sharebased Compensation Arrangement By Sharebased Payment Restricted Stock Awards Shares Outstanding Beginning SharebasedCompensationArrangementBySharebasedPaymentRestrictedStockAwardsSharesOutstandingBeginning	789074	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue	36.95
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P2Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	383406	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	12.3
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	244923	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	58.18
CY2023	oprx	Sharebased Compensation Arrangement By Sharebased Payment Restricted Stock Awards Shares Vested And Issued SharebasedCompensationArrangementBySharebasedPaymentRestrictedStockAwardsSharesVestedAndIssued	-141859	shares
CY2023	oprx	Sharebased Compensation Arrangement By Sharebased Payment Restricted Stock Awards Weighted Average Grant Date Fair Value Vested And Issued SharebasedCompensationArrangementBySharebasedPaymentRestrictedStockAwardsWeightedAverageGrantDateFairValueVestedAndIssued	31.38
CY2023	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	42489	shares
CY2023	oprx	Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Grant Date Fair Value Withheld And Cancelled ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueWithheldAndCancelled	32.47
CY2023Q4	oprx	Sharebased Compensation Arrangement By Sharebased Payment Restricted Stock Awards Shares Outstanding Beginning SharebasedCompensationArrangementBySharebasedPaymentRestrictedStockAwardsSharesOutstandingBeginning	743209	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue	18.62
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P1Y8M12D
CY2023	oprx	Granted Restricted Stock Description GrantedRestrictedStockDescription	The Company granted restricted stock units of 383,406 and 467,043 units in 2023 and 2022, respectively, and valued at $4,714,564 and $11,996,111, respectively. These restricted stock units vest over a period of 1 year to 5 years. The Company recognized expense of $7,791,917 and $10,789,203 in 2023 and 2022, respectively, related to these restricted stock units.
CY2023	oprx	Restricted Stock Granted Remains Value RestrictedStockGrantedRemainsValue	11106405	usd
CY2023	oprx	Remains To Be Recognized Over A Period RemainsToBeRecognizedOverAPeriod	P1Y11M12D
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	750130	usd
CY2023	oprx	Stock Issued During Period Shares Restricted Stocks Award Gross StockIssuedDuringPeriodSharesRestrictedStocksAwardGross	50305	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	750050	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	161698	shares
CY2023Q2	oprx	Grant Date Fair Value Over GrantDateFairValueOver	2500000	usd
CY2021Q4	oprx	Market Based Restricted Stock Units MarketBasedRestrictedStockUnits	182398	shares
CY2023	us-gaap	Loss Contingency Damages Awarded Value LossContingencyDamagesAwardedValue	1900000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	38290000	usd
CY2023Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	2000000	usd
CY2023Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	2059263	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	34230737	usd
CY2023Q4	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	40000000	usd
CY2023Q4	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	2300000	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	210737	usd
CY2023	oprx	Term Loan Percentage TermLoanPercentage	0.0125	pure
CY2023	us-gaap	Line Of Credit Facility Increase Decrease For Period Net LineOfCreditFacilityIncreaseDecreaseForPeriodNet	500000	usd
CY2023	us-gaap	Life Premiums As Percentage Of Gross Premiums LifePremiumsAsPercentageOfGrossPremiums	0.03	pure
CY2023	oprx	Leverage Description LeverageDescription	In addition, the Company is required to make a mandatory prepayment on March 31, of each year, commencing with 2025, equivalent to Excess Cash Flow multiplied by a percentage factor of 25%, if the leverage ratio is 3.60 to 1.00 or less, 50% if the leverage ratio is greater than 3.60 to 1 or less than or equal; to 4.10 to 1.00 and 75%, if the leverage ratio is greater than 4.10 to 1.00.
CY2023	us-gaap	Repayments Of Debt RepaymentsOfDebt	1700000	usd
CY2023	us-gaap	Contract With Customer Asset Sale ContractWithCustomerAssetSale	1200000	usd
CY2023Q4	us-gaap	Investment Interest Rate InvestmentInterestRate	0.085	pure
CY2023Q4	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0.141	pure
CY2023Q4	us-gaap	Receivable With Imputed Interest Premium ReceivableWithImputedInterestPremium	181895	usd
CY2023Q4	us-gaap	Long Term Debt Percentage Bearing Variable Interest Rate LongTermDebtPercentageBearingVariableInterestRate	0.196	pure
CY2023	us-gaap	Financing Interest Expense FinancingInterestExpense	5000000	usd
CY2023Q4	us-gaap	Loans Held For Sale Term LoansHeldForSaleTerm	P4Y
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	95765	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	100771	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	38850	usd
CY2023	us-gaap	Lease Cost LeaseCost	134615	usd
CY2022	us-gaap	Lease Cost LeaseCost	176555	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	260016	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	178082	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	113802	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	65866	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	45160	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	662926	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	69863	usd
CY2023Q4	oprx	Total Lease Liabilities TotalLeaseLiabilities	593063	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y2M1D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.067	pure
CY2023	oprx	Measurement Of Lease Liabilities MeasurementOfLeaseLiabilities	78875	usd
CY2023	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	91228	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	94564	usd
CY2022	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	101405	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	101433	usd
CY2023	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	As of December 31, 2023, the Company had net operating loss (“NOLs”) carry-forwards for federal income tax purposes of approximately $16.7 million, consisting of pre-2018 losses in the amount of approximately $3.3 million that expire from 2033 through 2037, and post-2017 losses in the amount of approximately $13.4 million that will never expire.
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	5284000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	2402000	usd
CY2023	oprx	Federal Income Tax State Tax Effect Net Of Federal Benefit FederalIncomeTaxStateTaxEffectNetOfFederalBenefit	569000	usd
CY2022	oprx	Federal Income Tax State Tax Effect Net Of Federal Benefit FederalIncomeTaxStateTaxEffectNetOfFederalBenefit	545000	usd
CY2023	oprx	Federal Income Tax Option Exercise Benefits Net Of Section162 M Limitations FederalIncomeTaxOptionExerciseBenefitsNetOfSection162MLimitations	-3100000	usd
CY2022	oprx	Federal Income Tax Option Exercise Benefits Net Of Section162 M Limitations FederalIncomeTaxOptionExerciseBenefitsNetOfSection162MLimitations	-268000	usd
CY2023	us-gaap	Asset Acquisition Consideration Transferred Transaction Cost AssetAcquisitionConsiderationTransferredTransactionCost	-360000	usd
CY2023	oprx	Federal Income Tax Other Adjustments FederalIncomeTaxOtherAdjustments	44922	usd
CY2022	oprx	Federal Income Tax Other Adjustments FederalIncomeTaxOtherAdjustments	221000	usd
CY2023	oprx	Federal Income Tax Expenses Benefit Value Allowance FederalIncomeTaxExpensesBenefitValueAllowance	5160000	usd
CY2022	oprx	Federal Income Tax Expenses Benefit Value Allowance FederalIncomeTaxExpensesBenefitValueAllowance	-2900000	usd
CY2023	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	7597922	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-97452	usd
CY2023	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	-97452	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	6488661	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1206713	usd
CY2023	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	7695374	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7597922	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.21	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4864000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5545000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3744000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3953000	usd
CY2023Q4	oprx	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	115000	usd
CY2022Q4	oprx	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	63000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	2533000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	789000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	126000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	103000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	16000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11720000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10492000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	12393000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	2102000	usd
CY2023Q4	oprx	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	-110000	usd
CY2022Q4	oprx	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	-63000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	-106000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	-198424	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	-59000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	12701424	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2330000	usd
CY2023Q4	oprx	Net Deferred Taxliability Assets NetDeferredTaxliabilityAssets	981424	usd
CY2022Q4	oprx	Net Deferred Taxliability Assets NetDeferredTaxliabilityAssets	-8162000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3356000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8162000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4337424	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4806000	usd
CY2023	oprx	Future Minimum Payments FutureMinimumPayments	24700000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	10600000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	8300000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	3300000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	2400000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	100000	usd
CY2023	us-gaap	Description Of Defined Contribution Pension And Other Postretirement Plans DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans	Under the terms of the plan, the Company matches 100% of the first 3% of payroll contributed by the employee and 50% of the next 2% of payroll contributed by the employee to a maximum of 4% of an employee’s payroll.
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	726660	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	489780	usd
CY2023	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	true
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments		usd
CY2022Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable		usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent		usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent		usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2022	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal		usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2022	us-gaap	Interest Expense InterestExpense		usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2022	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets		usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts		usd
CY2022	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges		usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
CY2022	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets		usd
CY2022	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments		usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet		usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2023	oprx	Reduction Of Evince Med Purchase Price For Amounts Previously Paid ReductionOfEvinceMedPurchasePriceForAmountsPreviouslyPaid		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023	us-gaap	Dilutive Securities DilutiveSecurities		usd
CY2023	oprx	Effect Of Dilutive Securities Shares EffectOfDilutiveSecuritiesShares		shares
CY2023	oprx	Effect Of Dilutive Securities Per Share Amount EffectOfDilutiveSecuritiesPerShareAmount
CY2022	us-gaap	Dilutive Securities DilutiveSecurities		usd
CY2022	oprx	Effect Of Dilutive Securities Shares EffectOfDilutiveSecuritiesShares		shares
CY2022	oprx	Effect Of Dilutive Securities Per Share Amount EffectOfDilutiveSecuritiesPerShareAmount
CY2023Q4	us-gaap	Assets Held In Trust AssetsHeldInTrust		usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2023	us-gaap	Production Related Impairments Or Charges ProductionRelatedImpairmentsOrCharges		usd
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt		usd
CY2022Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent		usd
CY2022Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense		usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent		usd
CY2022	us-gaap	Asset Acquisition Consideration Transferred Transaction Cost AssetAcquisitionConsiderationTransferredTransactionCost		usd
CY2022	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations		usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment		usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets		usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001448431

Files In Submission

Name	View Source	Status
0001213900-24-033000-index-headers.html	Edgar Link	pending
0001213900-24-033000-index.html	Edgar Link	pending
0001213900-24-033000.txt	Edgar Link	pending
0001213900-24-033000-xbrl.zip	Edgar Link	pending
ea0203848-10k_optimizerx.htm	Edgar Link	pending
ea020384801ex10-26_optimize.htm	Edgar Link	pending
ea020384801ex10-27_optimize.htm	Edgar Link	pending
ea020384801ex10-28_optimize.htm	Edgar Link	pending
ea020384801ex19-1_optimize.htm	Edgar Link	pending
ea020384801ex21-1_optimize.htm	Edgar Link	pending
ea020384801ex23-1_optimize.htm	Edgar Link	pending
ea020384801ex31-1_optimize.htm	Edgar Link	pending
ea020384801ex31-2_optimize.htm	Edgar Link	pending
ea020384801ex32-1_optimize.htm	Edgar Link	pending
ea020384801ex97-1_optimize.htm	Edgar Link	pending
ex10-26_001.jpg	Edgar Link	pending
ex10-27_001.jpg	Edgar Link	pending
ex23-1_001.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
oprx-20231231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
oprx-20231231_cal.xml	Edgar Link	unprocessable
oprx-20231231_def.xml	Edgar Link	unprocessable
oprx-20231231_lab.xml	Edgar Link	unprocessable
oprx-20231231_pre.xml	Edgar Link	unprocessable
ea0203848-10k_optimizerx_htm.xml	Edgar Link	completed
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OPRX
OptimizeRx Corp Stock $oprx

2024 Q2 Form 10-K Financial Statement

#000121390024033000 Filed on April 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPRX OptimizeRx Corp Stock $oprx

2024 Q2 Form 10-K Financial Statement

#000121390024033000 Filed on April 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPRX
OptimizeRx Corp Stock $oprx